Loading

Aurion Biotech

June 03, 2024
Company Presentation
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 1
Aurion Biotech is a privately held, clinical-stage biotech company, whose mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech completed a $120M Series C financing in 2022, and they are the recipient of the prestigious Prix Galien award for best start-up in biotech. Their lead candidate, AURN001, is in Phase 1/2 trials in the U.S. and Canada for the treatment of corneal edema secondary to corneal endothelial disease. This is the first allogenic, clinically validated cell therapy for corneal endothelial disease, having received regulatory approval in Japan. Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures.
Aurion Biotech
Company Website: https://aurionbiotech.com/
Lead Product in Development: AURN001

Company HQ City

Seattle

Company HQ State

Washington

Company HQ Country

United States

CEO/Top Company Official

Greg Kunst, CEO

Development Phase of Primary Product

Phase II
Speakers
Greg Kunst, MBA
CEO
Aurion Biotech
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS